4//SEC Filing
MOEBIUS HANS 4
Accession 0001209191-21-047601
CIK 0001620463other
Filed
Jul 20, 8:00 PM ET
Accepted
Jul 21, 4:47 PM ET
Size
13.3 KB
Accession
0001209191-21-047601
Insider Transaction Report
Form 4
MOEBIUS HANS
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2021-07-21$1.35/sh+12,610$17,024→ 14,665 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-07-21−12,610→ 0 totalExercise: $1.35Exp: 2029-06-25→ Common Stock (12,610 underlying) - Exercise/Conversion
Common Stock
2021-07-21$1.35/sh+15,762$21,279→ 30,427 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-07-21−15,762→ 15,763 totalExercise: $1.35Exp: 2029-08-14→ Common Stock (15,762 underlying) - Award
Common Stock
2021-05-18$14.45/sh+2,055$29,695→ 2,055 total
Footnotes (5)
- [F1]The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP Purchase Period (as defined in the ESPP) of September 17, 2020 through May 18, 2021. This transaction is also exempt under Rule 16b-3(c).
- [F2]The Purchase Period ended May 18, 2021 and is the Purchase Period comprising the Offering Period (as defined in the ESPP) that began September 17, 2020.
- [F3]In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the initial public offering price from the issuer's initial public offering.
- [F4]The shares subject to the option fully vested on April 1, 2021.
- [F5]One-fourth of the shares subject to the option vested on June 1, 2020 and one-fourth of the shares subject to the option vest on each year thereafter.
Documents
Issuer
Athira Pharma, Inc.
CIK 0001620463
Entity typeother
Related Parties
1- filerCIK 0001822494
Filing Metadata
- Form type
- 4
- Filed
- Jul 20, 8:00 PM ET
- Accepted
- Jul 21, 4:47 PM ET
- Size
- 13.3 KB